ASTRO: Oropharynx CA Survival Rates Worse With RT/Cetuximab
Inferior overall and progression - free survival for radiation/cetuximab versus radiation/cisplatin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Infections, Oncology, Radiology, Conference News, Source Type: news
TP53 Mutational Status and Cetuximab Benefit in Rectal CancerTP53 Mutational Status and Cetuximab Benefit in Rectal Cancer
Get the latest on locally advanced rectal cancer treatment from this updated analysis of the EXPERT-C trial. Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
FOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal CancersFOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal Cancers
In patients with KRAS exon 2 wild-type metastatic colorectal cancer (MCC) who received first-line FOLFIRI (fluorouracil, folinic acid and irinotecan), adding cetuximab rather than bevacizumab yielded longer overall survival. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ESMO: Erbitux No Help in Esophageal Ca (CME/CE)
(MedPage Today) -- Survival in esophageal cancer did not improve with the addition of cetuximab (Erbitux) to conventional chemoradiation, results of a randomized trial showed. The study was among several notable reports from the European Society for Medical Oncology World Congress on Gastrointestinal Cancer. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 2, 2014 Category: Primary Care Source Type: news
Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 29, 2014 Category: Science Source Type: news
Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 28, 2014 Category: Biology Source Type: news
Alchemia begins patient enrolment for Phase II trial of HA-Irinotecan and Erbitux
Australia-based Alchemia has started patient enrolment of the new clinical trial of HA-Irinotecan and Erbitux (cetuximab) called the CHIME trial. (Source: Drug Development Technology)
Source: Drug Development Technology - June 23, 2014 Category: Pharmaceuticals Source Type: news
Colon Cancer Alliance - high out-of-pocket costs
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine. Due to increased costs, patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition. The Affordable Care Act and Health Insurance Exchanges were intended to address the need for affordable care. The new Avelere study supports the patient stories we often hear. High copays and deductibles can create a fina...
Source: PHRMA - June 13, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
ASCO: Chemo Plus Avastin or Erbitux Boosts Colorectal Ca Survival
CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical trial. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 1, 2014 Category: Journals (General) Source Type: news
ASCO: Biologic Agents Plus Chemo Equal in Colon Ca
CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical trial. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 1, 2014 Category: Journals (General) Source Type: news
Bevacizumab, Cetuximab Have Similar Survival Benefits in CRCBevacizumab, Cetuximab Have Similar Survival Benefits in CRC
Adding either bevacizumab or cetuximab to chemotherapy yielded equal benefits in metastatic colorectal cancer (CRC). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Patients with metastatic colon cancer respond to new combination therapy
In an aggressive disease known for poor response rates, researchers found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. "What's promising is the fact that we're seeing these high response rates in early studies which suggests this could become a new standard of care down the line," one researcher said. "There's clearly some kind of synergistic activity with the combination." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 31, 2014 Category: Science Source Type: news
Patients with metastatic colon cancer respond to new combination therapy
(University of Texas M. D. Anderson Cancer Center) In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 31, 2014 Category: Global & Universal Source Type: news
Patients with metastatic colon cancer respond to new combination therapy
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center
found patients with advanced colorectal cancer responded well to a
combination therapy of the drugs vermurafenib, cetuximab and irinotecan. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - May 31, 2014 Category: Cancer & Oncology Source Type: news
JCI online ahead of print table of contents for May 16, 2014
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, May 16, 2014 in the JCI: 'Targeting microbial translocation attenuates SIV-mediated inflammation,' 'Estrogen underlies sex-specific responses to sildenafil,' 'Vaccine-induced cell population inhibits SIV vaccine efficacy,' 'Enhancing efficacy of the cancer drug cetuximab,' 'Beta-catenin-regulated myeloid cell adhesion and migration determine wound healing,' 'Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression,' and more. (Source:...
Source: EurekAlert! - Cancer - May 16, 2014 Category: Cancer & Oncology Source Type: news
